Urogen Pharma (NASDAQ:URGN – Get Free Report) and Pulmatrix (NASDAQ:PULM – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.
Institutional & Insider Ownership
91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 11.8% of Pulmatrix shares are held by institutional investors. 4.8% of Urogen Pharma shares are held by company insiders. Comparatively, 0.6% of Pulmatrix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
Urogen Pharma has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Urogen Pharma | $109.79 million | 19.26 | -$153.49 million | ($1.98) | -21.84 |
| Pulmatrix | $7.81 million | 0.67 | -$5.16 million | ($1.10) | -1.31 |
Pulmatrix has lower revenue, but higher earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Pulmatrix, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and price targets for Urogen Pharma and Pulmatrix, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Urogen Pharma | 1 | 1 | 8 | 0 | 2.70 |
| Pulmatrix | 1 | 0 | 0 | 0 | 1.00 |
Urogen Pharma presently has a consensus target price of $52.38, suggesting a potential upside of 21.10%. Given Urogen Pharma’s stronger consensus rating and higher probable upside, research analysts clearly believe Urogen Pharma is more favorable than Pulmatrix.
Profitability
This table compares Urogen Pharma and Pulmatrix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Urogen Pharma | -51.73% | N/A | -43.79% |
| Pulmatrix | N/A | -125.65% | -95.19% |
Summary
Urogen Pharma beats Pulmatrix on 9 of the 14 factors compared between the two stocks.
About Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
About Pulmatrix
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
